Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Baxter
Moodys
Dow
Boehringer Ingelheim

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for ITI-007


Email this page to a colleague

« Back to Dashboard

What is the drug development status for ITI-007?

ITI-007 is an investigational drug.

There have been 28 clinical trials for ITI-007. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2016.

The most common disease conditions in clinical trials are Hemophilia A, Schizophrenia, and Bipolar Disorder. The leading clinical trial sponsors are Intra-Cellular Therapies, Inc., Grifols Biologicals, LLC, and CSL Behring.

There are thirty-nine US patents protecting this investigational drug and two hundred and eighty-eight international patents.

Recent Clinical Trials for ITI-007
TitleSponsorPhase
SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisTakeda Pharmaceuticals North America, Inc.Phase 3
SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory UniversityPhase 3
Emicizumab PUPs and Nuwiq ITI StudyGenentech, Inc.Phase 3

See all ITI-007 clinical trials

Clinical Trial Summary for ITI-007

Top disease conditions for ITI-007
Top clinical trial sponsors for ITI-007

See all ITI-007 clinical trials

US Patents for ITI-007

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ITI-007 ⤷  Sign up for a Free Trial Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity INTRA-CELLULAR THERAPIES, INC. (New York, NY) ⤷  Sign up for a Free Trial
ITI-007 ⤷  Sign up for a Free Trial Organic compounds INTRA-CELLULAR THERAPIES, INC. (New York, NY) ⤷  Sign up for a Free Trial
ITI-007 ⤷  Sign up for a Free Trial Compounds and methods of use to treat schizophrenia INTRA-CELLULAR THERAPIES, INC. (New York, NY) ⤷  Sign up for a Free Trial
ITI-007 ⤷  Sign up for a Free Trial Preparation of certain substituted [((6bR,10aS)-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,- 2,3-de]quinoxalines and pharmaceutically acceptable salts thereof INTRA-CELLULAR THERAPIES, INC. (New York, NY) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ITI-007

Drugname Country Document Number Estimated Expiration Related US Patent
ITI-007 Denmark DK2968320 2033-03-15 ⤷  Sign up for a Free Trial
ITI-007 European Patent Office EP2968320 2033-03-15 ⤷  Sign up for a Free Trial
ITI-007 Spain ES2846823 2033-03-15 ⤷  Sign up for a Free Trial
ITI-007 Hong Kong HK1220615 2033-03-15 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Baxter
Moodys
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.